Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort

Neurology

Volumn 77, Issue 6, 2011, Pages 573-579

  Cossburn, M ^a   Pace, A A ^b   Jones, J ^c   Ali, R ^d   Ingram, G ^a   Baker, K ^a   Hirst, C ^a   Zajicek, J ^b   Scolding, N ^e   Boggild, M ^d   Pickersgill, T ^a   Ben Shlomo, Y ^e   Coles, A ^c   Robertson, N P ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b PENINSULA MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d THE WALTON CENTRE NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; LIVER ENZYME; METHYLPREDNISOLONE; STEROID; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; AUTOANTIBODY; CANCER ANTIBODY; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE SKIN DISEASE; AUTOIMMUNE THYROIDITIS; BULLOUS SKIN DISEASE; COHORT ANALYSIS; COLITIS; CONTROLLED STUDY; DISEASE SURVEILLANCE; DRUG DOSE REDUCTION; DRUG ERUPTION; FAMILY HISTORY; FEMALE; FOLLOW UP; GLOMERULONEPHRITIS; GRAVES DISEASE; HUMAN; HYPOTHYROIDISM; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NEUTROPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT; SMOKING; THROMBOCYTOPENIC PURPURA; UNITED KINGDOM; VITILIGO; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COUNSELING; GENETICS; IMMUNOLOGY; MIDDLE AGED; THYROID DISEASE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; COHORT STUDIES; COUNSELING; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROSPECTIVE STUDIES; RISK FACTORS; SMOKING; THYROID DISEASES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80053207130     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318228bec5     Document Type: Article

References (26)

1. Mavromatis B, Cheson BD. Monoclonal antibody therapy of chronic lymphocytic leukemia. J Clin Oncol 2003;21:1874-1881.
2. Greenwood J, Gorman SD, Routledge EG, Lloyd IS, Waldmann H. Engineering multiple-domain forms of the therapeutic antibody CAMPATH-1H: effects on complement lysis. Ther Immunol 1994;1:247-255.
3. Waldmann H. A personal history of the CAMPATH-1H antibody. Med Oncol 2002;19(suppl): S3-S9.
4. CAMMS Trial Investigators, Coles AJ, Compston DA, et al. Alemtuzumab vs interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;35:1786-1801.
5. Coles A, Deans J, Compston A. Campath-1H treatment for multiple sclerosis: lessons from the bedside for the bench. Clin Neurol Neurosurg 2004;106:270-274.
6. Coles AJ, Wing M, Smith S, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999;394:1691-1695.
7. Burek CL, Rose NR, Guire KE, et al. Human autoimmune thyroid disease: risk factors. Immunol Ser 1990;52:169-190.
8. Vestergaard P, Rejnmark L, Weeke J, et al. Smoking as a risk factor for Graves' disease, toxic nodular goitre and autoimmune hypothyroidism. Thyroid 2002;12:69-75.
9. Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006;253:98-108.
10. Hirst CL, Pace A, Pickersgill T, et al. Campath-1H treatment in patients with aggressive relapsing remitting multiple sclerosis. J Neurol 2008;255:231-238.
11. Marsh EA, Hirst CL, Llewelyn JG, et al. Alemtuzumab in the treatment of chronic immune demyelinating polyneuropathy. J Neurol Epub 2010 Jan 6.
12. King C, Ilic A, Koelsch K, Sarvetnick N. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 2004;117:265-277.
13. Jones JL, Phuah CL, Cox AL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 2009;119:2052-2061.
14. Niederwieser G, Buchinger W, Bonelli RM, et al. Prevalence of autoimmune thyroiditis and non-immune thyroid disease in multiple sclerosis. J Neurol 2003;250:672-675.
15. Broadley SA, Deans J, Sawcer SJ, Clayton D, Compston DA. Autoimmune disease in first-degree relatives of patients with multiple sclerosis: a UK survey. Brain 2000;123:1102-1111.
16. Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost 2006;4:2377-2383.
17. Munteis E, Segura N, Martinez J, Cuadrado E, Galvez A, Roquer J. Idiopathic thrombocytopenic purpura in patients with multiple sclerosis. Mult Scler 2006;12: S210. Abstract
18. Granier H, Bellard S, Nicolas X, Laborde JP, Talarmin F. Association of multiple sclerosis and autoimmune thrombopenia. Rev Med Interne 2001;22:1271-1272.
19. Kirby S, Brown MG, Murray TJ, et al. Prevalence of other autoimmune diseases in patients with multiple sclerosis. Mult Scler 2005;11: S29. Abstract
20. Brandsma CA, Hylkema MN, Geerlings M, et al. Increased levels of (class switched) memory B cells in the peripheral blood of current smokers. Respir Res 2009;10:108.
21. Nakamura Y, Miyata M, Ohba T, et al. Cigarette smoke extract induces thymic stromal lymphopoietin expression, leading to T (H) 2-type immune responses and airway inflammation. J Allergy Clin Immunol 2008;122:1208-1214.
22. Lambers C, Hacker S, Posch M, et al. T cell senescence and contraction of T cell repertoire diversity in patients with chronic obstructive pulmonary disease. Clin Exp Immunol 2009;155:466-475.
23. Wyatt RJ, Bridges RB, Halatek DG. Complement levels in cigarette smokers: elevation of serum concentrations of C5, C9, and C1-inhibitor. J Clin Lab Immunol 1981;6:131-135.
24. Lodovici M, Luceri C, De Filippo C, Romualdi C, Bambi F, Dolara P. Smokers and passive smokers gene expression profiles: correlation with the DNA oxidation damage. Free Radic Biol Med 2007;43:415-422.
25. Doyle I, Ratcliffe M, Walding A, et al. Differential gene expression analysis in human monocyte-derived macrophages: impact of cigarette smoke on host defence. Mol Immunol 2010;47:1058-1065.
26. Hedström AK, Bäärnhielm M, Olsson T, Alfredsson L. Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis. Neurology 2009;73:696-701.